跳至主要内容
临床试验/NCT00487123
NCT00487123已完成4 期

A Multi-Center, Randomized, Proof-of-Concept, Parallel Control Study With Remind Cap® in Patients With Essential Hypertension and Newly Treated With Valsartan+/-Hydrochlorothiazide (HCTZ)

Novartis1 个研究点 分布在 1 个国家开始时间: 2007年6月15日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
试验地点
1
主要终点
Compliance rate at month 3, 6 and post study month 1 will be assessed by pill count

研究概览

简要总结

This study will evaluate the efficacy of the reminder device Remind Cap® in improving patients' compliance in the consumption of Valsartan +/- Hydrochlorothiazide (HCTZ) in the treatment of hypertension

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with hypertension that have newly started using Valsartan+/-HCTZ

排除标准

  • Pregnancy or Hypersensitivity to Valsartan+/-HCTZ
  • Other protocol-defined inclusion/exclusion criteria may apply

结局指标

主要结局

Compliance rate at month 3, 6 and post study month 1 will be assessed by pill count

次要结局

  • Patient Adherence to study/follow up visits -Clinical Outcome Measurement: Mean sitting systolic BP and mean sitting diastolic BP -Patient's and Physician's Satisfaction Survey

研究者

发起方
Novartis
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验